ORION NUTRACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4 CAD | -.--% |
|
-.--% | -.--% |
| Mar. 13 | Joel Dumaresq Resigns as Director of Orion Nutraceuticals Inc | CI |
| Mar. 13 | Orion Nutraceuticals Inc. Announces Chief Financial Officer Changes | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 11.72M 16.12M |
|---|---|---|---|---|---|
| Net income 2022 | -2M -2.75M | Net income 2023 | - 0 | EV / Sales 2022 | - |
| Net Debt 2022 | 34.57K 47.53K | Net Debt 2023 | 86.34K 119K | EV / Sales 2023 | - |
| P/E ratio 2022 |
-4.47
x | P/E ratio 2023 |
-41.9
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 98.64% |
More Fundamentals
* Assessed data
More news
More press releases
5 years
0.14
5.13
10 years
0.1425.00
| Members of the board | Title | Age | Since |
|---|---|---|---|
Guy Bourgeois
CEO | Chief Executive Officer | - | 23-06-06 |
Amanda Boudreau
BRD | Director/Board Member | - | 23-06-06 |
Orion Nutraceuticals Inc. is a Canada-based company. The Company is primarily focused on re-purposing a United States food and drug administration approved drug to target asthma and chronic obstructive pulmonary disease (COPD).
Sector
Pharmaceuticals
Calendar
2024-04-30
- Q3 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 8.68M | |
| +37.12% | 6.02B | |
| -14.61% | 4.55B | |
| -10.58% | 3.13B | |
| +0.86% | 3.07B | |
| -0.94% | 2.57B | |
| +36.18% | 1.82B | |
| -10.82% | 1.63B | |
| -4.89% | 1.57B | |
| -12.50% | 1.54B |
- Stock Market
- Equities
- ORI Stock
